Clinical and psychometric validation of an EORTC questionnaire module, the EORTC QLQ-OES18, to assess quality of life in patients with oesophageal cancerJane Blazeby, Derek Alderson, Thierry Conroy et al.|European Journal of Cancer|2003Cited by 415
Peri-operative chemotherapy with or without bevacizumab in operable oesophagogastric adenocarcinoma (UK Medical Research Council ST03): primary analysis results of a multicentre, open-label, randomised phase 2–3 trialDavid Cunningham, Ruth E. Langley, Sally Stenning et al.|The Lancet Oncology|2017Cited by 286
Neoadjuvant cisplatin and fluorouracil versus epirubicin, cisplatin, and capecitabine followed by resection in patients with oesophageal adenocarcinoma (UK MRC OE05): an open-label, randomised phase 3 trialDerek Alderson, Ruth E. Langley, David Cunningham et al.|The Lancet Oncology|2017Cited by 223
Development of an EORTC disease-specific quality of life module for use in patients with gastric cancerC W Vickery, Derek Alderson, Juan Ignacio Arrarás et al.|European Journal of Cancer|2001Cited by 201
Neoadjuvant chemotherapy for resectable oesophageal and junctional adenocarcinoma: Results from the UK Medical Research Council randomised OEO5 trial (ISRCTN 01852072).Derek Alderson, David Cunningham, Ruth E. Langley et al.|Journal of Clinical Oncology|2015Cited by 80